Global Opportunities
with Regional Conviction

Chu Swee Yeok is the Chair and Founding Partner of August Global Partners (AGP), a fund management firm dedicated to investing in high-growth companies across the health and bio-ecosystem. With a career spanning decades at the forefront of strategic investment, she brings deep expertise and visionary leadership to AGP's mission of accelerating global healthcare innovation across Asia. Prior to founding AGP, Ms. Chu served as Senior Advisor to the Chairman of Singapore's EDBI, following her tenure as CEO, President, and Executive Director of the firm. Under her strong leadership, EDBI became a globally respected and trusted investor, building a diversified portfolio of over 200 private companies and funds across healthcare, digital innovation, financial services, and frontier engineering technologies. Ms. Chu's entrepreneurial journey with AGP is deeply rooted in her foundational role in shaping Singapore's biomedical sector. As the founding CEO of Bio*One Capital, she led the development of a pioneering billion-dollar fund that catalyzed innovation and commercialization in the industry — helping position Singapore as a global hub for biomedical research and enterprise. She also held senior leadership roles at EDB and A*STAR, where she played a pivotal role in crafting and executing national strategies that successfully advanced Singapore's biomedical ambitions. Beyond her leadership at AGP, Ms. Chu continues to contribute to industry growth through her service on the boards and advisory committees of public institutions, private enterprises, and publicly listed companies — championing innovation across diverse sectors. In recognition of her contribution to public service in healthcare, she was awarded the Public Service Medal (PBM) in August 2025.

Dr Basil Lui, Founding Partner of AGP, is a seasoned investor and healthcare technology expert. As former Managing Partner at EDBI, he led investments in groundbreaking healthcare ventures, including digital healthcare platforms, precision medicine companies, AI driven healthcare solution providers, and mRNA vaccine developers. His expertise spans regenerative technologies, connected health, and emerging fields like synthetic biology and AI in healthcare. Basil's investment acumen extends to early-stage deep-tech fund-of-funds, with a focus on regional healthcare funds. His background includes roles as a McKinsey consultant, APAC President of a semiconductor EDA company, and academic positions at NUS and Cambridge University. With a PhD from Cambridge and multiple patents to his name, Basil combines deep technical knowledge with strategic investment insights, driving innovation in healthcare and emerging technologies.

Davian is a Partner of AGP. Prior to this he was the Senior Principal of Investments at EDBI where he was responsible for originating, leading and negotiating investments in areas such as Manufacturing/Advanced Manufacturing, Healthcare Services and Technology. Specifically, Davian successfully led several healthcare investment transactions in services and industrial manufacturing such as Dontia Alliance, a pan-Asian specialist focused dental services company; Meiban, an Asian based medtech manufacturer; and Esco Lifesciences, a global medical equipment and devices brand and manufacturer. Before EDBI, he was responsible for strategic investments and divestiture at Aalst-Wilmar, an associate company of Wilmar International focused on industrial chocolate and cocoa and prior to that, focused on growth and buyout transactions at BXR Group, an international private investment group. Davian started his investment career at Credence Partners (now known as Altara Ventures), a Southeast Asian small/mid cap focused private equity fund. Davian's overall deal experience ranges widely, from minority stake growth transactions and leveraged buyouts, to M&As and joint ventures. He began his career at PrimePartners Corporate Finance. He is a qualified CPA (Australia) and graduated with a Master of Applied Finance from Macquarie University and a Bachelor of Commerce from The Australian National University.

Jude is responsible for establishing and managing all aspects of finance, compliance and operational matters in relation to AGP and its funds. He started his career at a Big 4 accounting firm in Singapore with a 3-year London secondment. He was then Vice President at GIC's Enterprise Strategy department. Prior to AGP, he was a pioneering team member of Greenwillow Capital Management. Jude graduated from NTU with a Bachelor of Accountancy (First Class Honours) and is a Chartered Accountant (ICAEW).

Shawn is a Venture Partner at AGP and an investment professional with over 20 years' experience in both private and public equity investments. He is currently the Managing Director of Axon Alpha Advisors, a family office investor with a global mandate and healthcare portfolio which includes medical devices, oncology drug development and digital health solutions. Prior to this, Shawn led private equity, technology focused investments at Novo Tellus Capital and EDBI. At Novo Tellus he led investments into companies providing advanced automation solutions for biomedical end products and at EDBI he was responsible for the Strategic Growth Programme. Some of his previous healthcare investments included Biosensors Ltd, Hummingbird Bioscience, Inovio Pharmaceutical Inc, BotMD, and Hyphens. He holds a Bachelor's with Honours Degree in Genetics and Molecular Biology from Glasgow University, UK, and a Master's Degree in Applied Finance from Adelaide University, Australia.

Jeong Shing (JS) is a Venture Partner at AGP with over 15 years of global healthcare experience across corporate pharma, technology management and venture capital, including incubating and building early stage life science companies. He was Partner at EDBI, the strategic venture arm of the Economic Development Board of Singapore, leading healthcare investments in biotech, medtech, digital health and life science tools, as well as Fund of Fund investments. Prior to EDBI, JS oversaw investments at Venturecraft, a Singapore based boutique venture capital firm and multi-family office. He successfully set up a digital health incubator supported by the Singapore government and nurtured several successful local start up companies such as Mirxes, US2.ai, Hearti Labs and Aktivo. He also established a life science accelerator in Hangzhou China. JS earned First Class Honours Degrees in Bioengineering and Chemical Engineering from the National University of Singapore, and holds an MBA with distinction from the University of Cambridge, specializing in Private Equity.

Warren is part of the AGP Investments team, where his grounding in both life sciences and finance equips him to translate scientific promise into investment conviction. Prior to AGP, Warren was at SGInnovate, evaluating venture deals and building corporate-startup partnerships across the healthcare and agrifood verticals. Before that, he was an innovation consultant at Alcimed, supporting corporates through technology scouting and commercial strategy. Warren holds a PhD and BSc (First Class Honours) in Life Sciences from the National University of Singapore, where his doctoral research applied quantitative LC-MS panels and multiomics to characterise cardiovascular disease. He also holds a BSc (First Class Honours) in Applied Accounting from Oxford Brookes University and is a CFA charterholder — reflecting his belief that the best healthcare investors speak both the language of science and of capital.

Chris Koh is a multifaceted professional with a strong background in entrepreneurship, marketing, operations, and trading. He holds a Bachelor of Commerce with double majors in Economics and Finance from Monash University, Melbourne. Chris has essential experience in an SME, where he played a key role in marketing, operations, and business development with various industry stakeholders. He has also previously worked as an independent trader, specializing in funding arbitrage, market analysis, and risk-reward decision-making across diverse financial markets.

Jerlin is an adaptable administrative professional with experience in data review, scheduling, stakeholder engagement, event logistics, and customer service across public and private sector operations in Singapore. She was twice recognized with awards for good leadership and service.